Core Viewpoint - The report by CMB International initiates coverage of Jinfang Pharmaceutical-B (02595) with a "Buy" rating and a target price of HKD 51, highlighting the company's strong management team and innovative drug pipeline focused on challenging RAS targets [1] Group 1: Product Pipeline and Innovation - The company has developed a diversified product pipeline centered around the difficult-to-drug RAS family members, leveraging deep understanding and successful R&D experience to create a candidate matrix that includes KRASG12C/G12D and pan-RAS, among others [2] - The product pipeline extends beyond RAS targets to include other significant indications such as tumors, cachexia, autoimmune, and inflammatory diseases, targeting market opportunities with favorable competitive landscapes [2] Group 2: Clinical Data and Competitive Advantage - The competitive advantage in RAS-targeted drug development is evident in the clinical data for GFH925 and GFH375, with GFH925 showing superior efficacy in 2L+ KRASG12C mutation NSCLC compared to overseas competitors and comparable or better results against domestic rivals [3] - GFH375 is among the first globally to enter Phase III clinical trials for KRASG12D, with promising preliminary data in third-line pancreatic cancer [3] - The dual antibody GDF15/IL-16 (GFS202A) shows early advantages in tolerability and activity compared to single-target drugs [3] Group 3: Management and Strategic Partnerships - The company has assembled a core management team with an average of over 20 years of industry experience, achieving a record of six years from project initiation to market launch for GFH925 [4] - The company actively seeks diverse global development opportunities and strategically selects partners to create value through complementary strengths, collaborating with notable firms such as Innovent Biologics, Merck, and Verastem [4] Group 4: Financial Projections and Valuation - The company is projected to achieve revenues of RMB 1.09 billion, 0.85 billion, and 1.18 billion in 2025-2027, primarily driven by sales of GFH925 in China and overseas collaboration for GFH375 [5] - Based on a DCF valuation model, the target price of HKD 51 corresponds to a 2.3x revenue peak sales multiple and an 87% potential upside [5] - Future focus includes monitoring the sales ramp-up of GFH925 post-reimbursement inclusion and additional data readouts from the RAS pipeline [5]

Core Viewpoint - The Chinese innovative pharmaceutical industry is undergoing a historic transformation, shifting from "fast followers" to "original creators," supported by solid data and market performance [1]. Group 1: Industry Overview - China's pharmaceutical industry is the second largest globally, with innovative drugs accounting for approximately 30% of global research [1]. - By 2025, the total value of innovative drug licensing transactions in China is expected to exceed $130 billion, with over 150 transactions, marking historical highs [1]. - The increase in competitiveness and cost-effectiveness of Chinese pharmaceutical assets is driving the industry into a critical phase of "innovation realization + global layout" [1]. Group 2: Regional Development - Shanghai's Pudong district is becoming a core hub for the global market connection of China's biopharmaceutical industry, with significant achievements in innovative drug approvals and business development transactions [1]. - By 2025, Pudong has approved 4 CAR-T products (30% of the global total) and 7 Class 1 new drugs (14% of the national total), with business development transaction amounts reaching $20.4 billion (14% of the global total) [1]. Group 3: Competitive Advantages - Chinese innovative pharmaceutical companies are gaining a competitive edge in the global market due to their speed and cost-effectiveness, being able to advance drug discovery 2-3 times faster and recruit clinical trial patients 2-5 times faster than international counterparts [3]. - The cost per patient for clinical trials in China is only half that of Europe and the US [3]. Group 4: Business Development Collaborations - Companies like Maiwei Biopharma and Jinsai Pharmaceutical are forming significant overseas business development collaborations, enhancing China's global competitiveness in innovative drugs [3][5]. - Maiwei Biopharma has accelerated its business development efforts, securing exclusive licensing agreements for innovative therapies within months of initial meetings [3][4]. Group 5: Full-Chain Layout - A number of innovative pharmaceutical companies are rapidly constructing comprehensive overseas layouts covering research, registration, and sales, transitioning from "licensing out" to "commercialization abroad" [9]. - By 2024, Pudong is expected to have over 20 innovative drugs achieving commercial sales, with total sales exceeding 11.6 billion yuan [9]. Group 6: Source Innovation - The market consensus is that only companies with source innovation capabilities, quality business development potential, and global layout abilities can effectively meet global market demands and achieve high valuations [16]. - Companies like Jinfang Pharmaceutical are focusing on unique therapeutic areas and avoiding following trends, which positions them favorably in the global market [17]. Group 7: Industry Ecosystem - The rise of China's innovative pharmaceutical industry is attributed to years of policy guidance, technological accumulation, and capital cultivation, leading to a critical growth inflection point [21]. - The unique industrial atmosphere, quality talent pool, and complete industrial chain in Zhangjiang are considered core advantages for companies operating in the region [21][22]. Group 8: Future Outlook - The Pudong district is set to enhance its support for the biopharmaceutical industry, aiming to become a global hub for innovative drug launches and scientific entrepreneurship [23]. - The ongoing development of a differentiated industrial linkage pattern is expected to further support the growth of the life sciences industry in the region [23]. Group 9: Conclusion - The path of globalization for Chinese innovative drugs is deepening, supported by core industrial hubs like Pudong and the continuous upgrading of companies' innovation and internationalization capabilities [24].